The Journal of Bone & Joint Surgery reports the findings of a 4-year trial comparing outcomes of total ankle arthroplasty (TAA) versus ankle arthrodesis (AA) in patients with severe ankle arthritis; finding that while both groups improved, TAA was associated with less pain and better function after 4 years.
All News
Erosive hand osteoarthritis (EHOA) was studied as part of the Osteoarthritis Initiative, and shown to increase with advanced age and female sex, with developmental findings to suggest that EHOA as a disorder of skeletal frailty.
NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
A randomized clinical trial of patients with CMC1 osteoarthritis shows modest benefits when a combination of conservative treatments (education, splinting, hand exercises, 1% diclofenac sodium gel) was used compared to education alone. While there were small to medium benefits with regard to hand function, there was no benefit in pain outcomes.
Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.
In the United Kingdom, where it is estimated that chronic pain affects one‑third to one‑half of the population, NICE (National Institute for Health and Care Excellence) has recently released an updated guideline on the management of chronic pain for people aged 16 years and over.
Total knee replacement (TKR) in obese patients with end-stage knee osteoarthritis appears to be a beneficial and cost-effective strategy for treating. The only potential limitation is a greater risk for adverse events in those with a body mass index (BMI) of 40 kg/m2 or greater.
Fractures of the spine and abdominal aortic calcification (AAC) can both be visualized with spinal imaging; a new report shows that finding both radiographic vertebral fracture and AAC on the same lateral spine images may predict the risk of future incident major osteoporotic fracture i
A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).
